Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...
The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.
Delaying noncardiac surgeries for three to six months following a heart attack appears safer for those who undergo r ...
For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...
The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions ...
AFib is the most common type of heart arrythmia2. Left untreated, it increases risk of stroke, heart failure, myocardial ...
One study suggests these drugs could increase depression risk in heart attack survivors who retained normal heart pumping ...
In MI patients with preserved heart function, beta-blockers are linked to higher depressive symptoms, indicating a need for ...
WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...
A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...
A history of HDP is linked to increased risks of myocardial infarction, whether that’s with obstructive coronary arteries or ...
The study found similar patterns in men and women, although there were some differences, especially for myocardial infarction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback